View Financial HealthaXichem 配当と自社株買い配当金 基準チェック /06aXichem配当金を支払った記録がありません。主要情報n/a配当利回り-0.4%バイバック利回り総株主利回り-0.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jan 15aXichem AB Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance SupplementaXichem AB announced the formal publication of its latest clinical trial, "Acute phenylcapsaicin supplementation improves exercise performance in CrossFit trained adults", in the Journal of the International Society of Sports Nutrition. Following the release of preliminary findings in March 2025, this final peer-reviewed publication provides the definitive scientific foundation for aXivite (phenylcapsaicin) in the elite sports and high-intensity functional fitness sectors. The randomized, triple-blind, placebo-controlled crossover trial, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite delivers significant physiological advantages: supplemented athletes achieved higher loads and repetition counts in deep squats at 70% 1RM; aXivite enabled participants to maintain weightlifting performance throughout grueling rounds, particularly in the final stages of the workout where fatigue typically peaks; data showed a statistically significant reduction in Delayed-Onset Muscle Soreness at both 24 and 48 hours post-exercise, allowing for faster returns to peak training capacity. This publication marks the latest milestone in a calculated development trajectory. aXichem has systematically built a scientific dossier for aXivite: in 2021, establishing metabolic bioequivalence to natural capsaicin with superior bioavailability and early gut health validation; in 2022-2023, validating metabolic support and weight management, followed by resistance training and aerobic capacity breakthroughs; in 2025, defining the high-intensity performance category through this definitive CrossFit study. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.お知らせ • Dec 01+ 5 more updatesaXichem AB, Annual General Meeting, Jun 17, 2026aXichem AB, Annual General Meeting, Jun 17, 2026.お知らせ • May 17aXichem AB, Annual General Meeting, Jun 18, 2025aXichem AB, Annual General Meeting, Jun 18, 2025, at 10:00 W. Europe Standard Time. Location: at the companys offices at sodergatan 26, malmo Swedenお知らせ • Jan 21+ 5 more updatesaXichem AB to Report Fiscal Year 2024 Results on Feb 27, 2025aXichem AB announced that they will report fiscal year 2024 results on Feb 27, 2025Reported Earnings • Aug 28Second quarter 2024 earnings released: kr0.032 loss per share (vs kr0.25 loss in 2Q 2023)Second quarter 2024 results: kr0.032 loss per share (improved from kr0.25 loss in 2Q 2023). Revenue: kr6.13m (up kr5.44m from 2Q 2023). Net loss: kr1.28m (loss narrowed 77% from 2Q 2023).お知らせ • May 23aXichem AB, Annual General Meeting, Jun 19, 2024aXichem AB, Annual General Meeting, Jun 19, 2024, at 10:00 W. Europe Standard Time. Location: in the company`s premises, sodergatan 26, malmo SwedenNew Risk • Apr 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$165k). Market cap is less than US$10m (€5.56m market cap, or US$5.90m).お知らせ • Mar 28aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million.aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,761,858 Price\Range: SEK 7.5 Transaction Features: Rights Offeringお知らせ • Mar 13OmneDiem Launches Two New ProductsaXichem AB (publ), announced that the provider of dietary supplements OmneDiemis launching two new products, formulated with aXichem's innovative ingredient aXivite, targeting the United States market. These launches represent an expansion of aXivite's applications in the fitness and wellness sectors, underscoring aXichem's commitment to broadening its global market presence and customer base. Body6, a bodybuilding and fitness brand, is set to bring important innovations in the market with the introduction of its Ready-To-Drink (RTD) pre-workout supplement powered by aXichem's aXivite. This innovative product is specifically designed to meet the needs of fitness enthusiasts and bodybuilders, offering an unparalleled boost in performance and energy. Body6 will leverage its partnership with Planet Fitness to make the pre-workout supplement accessible to a wide audience. Additionally, Body6 will feature the pre-workout and its Thermogenic Fat Management product at major national and regional fitness and bodybuilding events, including the prestigious Arnold Classic. OmneDiem is set to introduce a new product in the e-commerce and retail sectors with the launch of MaxRep Elite, a cutting-edge supplement designed to elevate workout performance and endurance. Available through various e-commerce platforms, distributors, retailers, and a network of fitness-oriented health care practitioners, MaxRep Elite aim to become the go-to choice for individuals seeking to maximize their workout potential and achieve their fitness goals.Reported Earnings • Mar 06Full year 2023 earnings released: kr1.03 loss per share (vs kr1.04 loss in FY 2022)Full year 2023 results: kr1.03 loss per share. Net loss: kr20.8m (loss widened 21% from FY 2022).Reported Earnings • Nov 24Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.32 loss in 3Q 2022)Third quarter 2023 results: kr0.21 loss per share (improved from kr0.32 loss in 3Q 2022). Revenue: kr328.0k (up 25% from 3Q 2022). Net loss: kr4.54m (loss narrowed 14% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 25First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.21 loss in 1Q 2022)First quarter 2023 results: kr0.29 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr4.76m (loss widened 34% from 1Q 2022). Revenue is forecast to grow 126% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.Reported Earnings • Mar 06Full year 2022 earnings released: kr1.04 loss per share (vs kr0.92 loss in FY 2021)Full year 2022 results: kr1.04 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr5.22m (up 20% from FY 2021). Net loss: kr17.3m (loss widened 14% from FY 2021). Revenue is forecast to grow 109% p.a. on average during the next 2 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 07aXichem AB to Report Fiscal Year 2022 Final Results on May 26, 2023aXichem AB announced that they will report fiscal year 2022 final results on May 26, 2023Reported Earnings • Nov 25Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.18 loss in 3Q 2021)Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.18 loss in 3Q 2021). Net loss: kr5.25m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 125% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 24+ 4 more updatesaXichem AB to Report Q3, 2023 Results on Nov 22, 2023aXichem AB announced that they will report Q3, 2023 results on Nov 22, 2023Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering aXichem expects the company to break even for the first time. New forecast suggests the company will make a profit of kr32.0m in 2024. Average annual earnings growth of 113% is required to achieve expected profit on schedule.Reported Earnings • Aug 28Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2021)Second quarter 2022 results: kr0.32 loss per share (down from kr0.24 loss in 2Q 2021). Revenue: kr702.0k (up kr642.0k from 2Q 2021). Net loss: kr5.20m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 26First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.20 loss in 1Q 2021)First quarter 2022 results: kr0.21 loss per share (down from kr0.20 loss in 1Q 2021). Revenue: kr538.0k (up kr486.0k from 1Q 2021). Net loss: kr3.56m (loss widened 13% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Jan Gustavsson was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr0.92 loss per share (down from kr0.85 loss in FY 2020). Net loss: kr15.1m (loss widened 12% from FY 2020). Revenue exceeded analyst estimates by 45%. Over the next year, revenue is forecast to grow 1,027%, compared to a 6.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 22First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)First quarter 2021 results: Net loss: kr3.15m (loss widened 2.2% from 1Q 2020).お知らせ • Mar 13+ 3 more updatesaXichem AB to Report Q1, 2021 Results on May 20, 2021aXichem AB announced that they will report Q1, 2021 results on May 20, 2021Is New 90 Day High Low • Feb 19New 90-day low: €4.00The company is down 18% from its price of €4.89 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period.Is New 90 Day High Low • Jan 28New 90-day low: €4.46The company is down 3.0% from its price of €4.60 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 28% over the same period.お知らせ • Nov 25aXichem Signs Agreement with BART Regarding Distribution and Sales of aXivite® in PolandaXichem AB (publ), has signed a marketing, sales and distribution agreement with the Polish company Bart Spólka Sp.k. Under the agreement BART has the exclusive right to distribute and sell aXichem's capsaicin analogue product, aXivite, on the Polish market. Entering this the agreement with BART aXichem has added yet another well-established distributor in the food supplement and nutrition segment in Europe. BART not only has the sales and distribution knowledge, but also, within its organization, through two innovative subsidiaries, resources in production and product development.Is New 90 Day High Low • Sep 23New 90-day low: €4.40The company is down 25% from its price of €5.86 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.決済の安定と成長配当データの取得安定した配当: A6Xの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: A6Xの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場aXichem 配当利回り対市場A6X 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (A6X)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.6%業界平均 (Chemicals)3.8%アナリスト予想 (A6X) (最長3年)n/a注目すべき配当: A6Xは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: A6Xは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: A6Xの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: A6Xが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 16:57終値2026/05/07 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋aXichem AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Johan SvantessonRedeye
お知らせ • Jan 15aXichem AB Announces Publication of CrossFit Study in Leading Sports Journal - Validates aXivite as a High-Intensity Performance SupplementaXichem AB announced the formal publication of its latest clinical trial, "Acute phenylcapsaicin supplementation improves exercise performance in CrossFit trained adults", in the Journal of the International Society of Sports Nutrition. Following the release of preliminary findings in March 2025, this final peer-reviewed publication provides the definitive scientific foundation for aXivite (phenylcapsaicin) in the elite sports and high-intensity functional fitness sectors. The randomized, triple-blind, placebo-controlled crossover trial, conducted by Dr. Pablo Jiménez Martínez and his team in Spain, examined 50 trained CrossFit athletes (25 male, 25 female). The results demonstrate that a single 2.5 mg dose of aXivite delivers significant physiological advantages: supplemented athletes achieved higher loads and repetition counts in deep squats at 70% 1RM; aXivite enabled participants to maintain weightlifting performance throughout grueling rounds, particularly in the final stages of the workout where fatigue typically peaks; data showed a statistically significant reduction in Delayed-Onset Muscle Soreness at both 24 and 48 hours post-exercise, allowing for faster returns to peak training capacity. This publication marks the latest milestone in a calculated development trajectory. aXichem has systematically built a scientific dossier for aXivite: in 2021, establishing metabolic bioequivalence to natural capsaicin with superior bioavailability and early gut health validation; in 2022-2023, validating metabolic support and weight management, followed by resistance training and aerobic capacity breakthroughs; in 2025, defining the high-intensity performance category through this definitive CrossFit study. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.
お知らせ • Dec 01+ 5 more updatesaXichem AB, Annual General Meeting, Jun 17, 2026aXichem AB, Annual General Meeting, Jun 17, 2026.
お知らせ • May 17aXichem AB, Annual General Meeting, Jun 18, 2025aXichem AB, Annual General Meeting, Jun 18, 2025, at 10:00 W. Europe Standard Time. Location: at the companys offices at sodergatan 26, malmo Sweden
お知らせ • Jan 21+ 5 more updatesaXichem AB to Report Fiscal Year 2024 Results on Feb 27, 2025aXichem AB announced that they will report fiscal year 2024 results on Feb 27, 2025
Reported Earnings • Aug 28Second quarter 2024 earnings released: kr0.032 loss per share (vs kr0.25 loss in 2Q 2023)Second quarter 2024 results: kr0.032 loss per share (improved from kr0.25 loss in 2Q 2023). Revenue: kr6.13m (up kr5.44m from 2Q 2023). Net loss: kr1.28m (loss narrowed 77% from 2Q 2023).
お知らせ • May 23aXichem AB, Annual General Meeting, Jun 19, 2024aXichem AB, Annual General Meeting, Jun 19, 2024, at 10:00 W. Europe Standard Time. Location: in the company`s premises, sodergatan 26, malmo Sweden
New Risk • Apr 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr21m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$165k). Market cap is less than US$10m (€5.56m market cap, or US$5.90m).
お知らせ • Mar 28aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million.aXichem AB has completed a Composite Units Offering in the amount of SEK 28.213935 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 3,761,858 Price\Range: SEK 7.5 Transaction Features: Rights Offering
お知らせ • Mar 13OmneDiem Launches Two New ProductsaXichem AB (publ), announced that the provider of dietary supplements OmneDiemis launching two new products, formulated with aXichem's innovative ingredient aXivite, targeting the United States market. These launches represent an expansion of aXivite's applications in the fitness and wellness sectors, underscoring aXichem's commitment to broadening its global market presence and customer base. Body6, a bodybuilding and fitness brand, is set to bring important innovations in the market with the introduction of its Ready-To-Drink (RTD) pre-workout supplement powered by aXichem's aXivite. This innovative product is specifically designed to meet the needs of fitness enthusiasts and bodybuilders, offering an unparalleled boost in performance and energy. Body6 will leverage its partnership with Planet Fitness to make the pre-workout supplement accessible to a wide audience. Additionally, Body6 will feature the pre-workout and its Thermogenic Fat Management product at major national and regional fitness and bodybuilding events, including the prestigious Arnold Classic. OmneDiem is set to introduce a new product in the e-commerce and retail sectors with the launch of MaxRep Elite, a cutting-edge supplement designed to elevate workout performance and endurance. Available through various e-commerce platforms, distributors, retailers, and a network of fitness-oriented health care practitioners, MaxRep Elite aim to become the go-to choice for individuals seeking to maximize their workout potential and achieve their fitness goals.
Reported Earnings • Mar 06Full year 2023 earnings released: kr1.03 loss per share (vs kr1.04 loss in FY 2022)Full year 2023 results: kr1.03 loss per share. Net loss: kr20.8m (loss widened 21% from FY 2022).
Reported Earnings • Nov 24Third quarter 2023 earnings released: kr0.21 loss per share (vs kr0.32 loss in 3Q 2022)Third quarter 2023 results: kr0.21 loss per share (improved from kr0.32 loss in 3Q 2022). Revenue: kr328.0k (up 25% from 3Q 2022). Net loss: kr4.54m (loss narrowed 14% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 25First quarter 2023 earnings released: kr0.29 loss per share (vs kr0.21 loss in 1Q 2022)First quarter 2023 results: kr0.29 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr4.76m (loss widened 34% from 1Q 2022). Revenue is forecast to grow 126% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Mar 06Full year 2022 earnings released: kr1.04 loss per share (vs kr0.92 loss in FY 2021)Full year 2022 results: kr1.04 loss per share (further deteriorated from kr0.92 loss in FY 2021). Revenue: kr5.22m (up 20% from FY 2021). Net loss: kr17.3m (loss widened 14% from FY 2021). Revenue is forecast to grow 109% p.a. on average during the next 2 years, compared to a 2.0% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 07aXichem AB to Report Fiscal Year 2022 Final Results on May 26, 2023aXichem AB announced that they will report fiscal year 2022 final results on May 26, 2023
Reported Earnings • Nov 25Third quarter 2022 earnings released: kr0.32 loss per share (vs kr0.18 loss in 3Q 2021)Third quarter 2022 results: kr0.32 loss per share (further deteriorated from kr0.18 loss in 3Q 2021). Net loss: kr5.25m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 125% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 24+ 4 more updatesaXichem AB to Report Q3, 2023 Results on Nov 22, 2023aXichem AB announced that they will report Q3, 2023 results on Nov 22, 2023
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering aXichem expects the company to break even for the first time. New forecast suggests the company will make a profit of kr32.0m in 2024. Average annual earnings growth of 113% is required to achieve expected profit on schedule.
Reported Earnings • Aug 28Second quarter 2022 earnings released: kr0.32 loss per share (vs kr0.24 loss in 2Q 2021)Second quarter 2022 results: kr0.32 loss per share (down from kr0.24 loss in 2Q 2021). Revenue: kr702.0k (up kr642.0k from 2Q 2021). Net loss: kr5.20m (loss widened 33% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 26First quarter 2022 earnings released: kr0.21 loss per share (vs kr0.20 loss in 1Q 2021)First quarter 2022 results: kr0.21 loss per share (down from kr0.20 loss in 1Q 2021). Revenue: kr538.0k (up kr486.0k from 1Q 2021). Net loss: kr3.56m (loss widened 13% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (5 non-independent directors). Chairman of the Board Jan Gustavsson was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 18Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr0.92 loss per share (down from kr0.85 loss in FY 2020). Net loss: kr15.1m (loss widened 12% from FY 2020). Revenue exceeded analyst estimates by 45%. Over the next year, revenue is forecast to grow 1,027%, compared to a 6.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 22First quarter 2021 earnings released: kr0.20 loss per share (vs kr0.19 loss in 1Q 2020)First quarter 2021 results: Net loss: kr3.15m (loss widened 2.2% from 1Q 2020).
お知らせ • Mar 13+ 3 more updatesaXichem AB to Report Q1, 2021 Results on May 20, 2021aXichem AB announced that they will report Q1, 2021 results on May 20, 2021
Is New 90 Day High Low • Feb 19New 90-day low: €4.00The company is down 18% from its price of €4.89 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period.
Is New 90 Day High Low • Jan 28New 90-day low: €4.46The company is down 3.0% from its price of €4.60 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 28% over the same period.
お知らせ • Nov 25aXichem Signs Agreement with BART Regarding Distribution and Sales of aXivite® in PolandaXichem AB (publ), has signed a marketing, sales and distribution agreement with the Polish company Bart Spólka Sp.k. Under the agreement BART has the exclusive right to distribute and sell aXichem's capsaicin analogue product, aXivite, on the Polish market. Entering this the agreement with BART aXichem has added yet another well-established distributor in the food supplement and nutrition segment in Europe. BART not only has the sales and distribution knowledge, but also, within its organization, through two innovative subsidiaries, resources in production and product development.
Is New 90 Day High Low • Sep 23New 90-day low: €4.40The company is down 25% from its price of €5.86 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 8.0% over the same period.